A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer.
第一作者:
E C,Kohn
第一单位:
Medical Ovarian Cancer Section, Clinical Pharmacology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.
作者:
主题词
成年人(Adult);老年人(Aged);抗肿瘤药, 烷基化(Antineoplastic Agents, Alkylating);抗肿瘤药, 植物(Antineoplastic Agents, Phytogenic);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);癌(Carcinoma);顺铂(Cisplatin);环磷酰胺(Cyclophosphamide);女(雌)性(Female);人类(Humans);中年人(Middle Aged);肿瘤分期(Neoplasm Staging);卵巢肿瘤(Ovarian Neoplasms);紫杉酚(Paclitaxel);预后(Prognosis);存活率分析(Survival Analysis);治疗结果(Treatment Outcome)
DOI
10.1006/gyno.1996.0213
PMID
8751547
发布时间
2015-11-19
- 浏览16

Gynecologic oncology
181-91页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文